Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type (Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (M

Hematopoietic Stem Cell Transplantation (HSCT) Market, by Transplant Type (Allogeneic and Autologous), by Indication (Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), and Other Non-malignant Disorders), by Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), and Cord Blood Transplant (CBT))and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow, or umbilical cord blood are transplanted into the patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources; 1) autologous, that uses stem cells from the patient’s own body, 2) and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.
Market Dynamics
The global hematopoietic stem cell transplantation market is expected to witness significant growth during the forecast period owing to the increasing prevalence of leukemia and lymphoma. According to Center for Disease Control and Prevention (CDC), in the U.S., around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). According to the same source the condition is more prevalent among men than women. Leukemia accounts for around 3% of all new cancer cases.
Key features of the study:
This report provides in-depth analysis of the global hematopoietic stem cell transplantation market, market size (US$ Mn), and compound annual growth rate (CAGR %) for the forecast period 2022-2028, considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hematopoietic stem cell transplantation market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
The global hematopoietic stem cell transplantation market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hematopoietic stem cell transplantation market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type:
Allogeneic
Autologous
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
North America
By Country:
U.S.
Canada
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukaemia (AML)
Acute Lymphoblastic Leukaemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Transplant Type:
Allogeneic
Autologous
By Indication:
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Other Non-Malignant Disorders
By Application:
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Company Profiles
Pluristem Therapeutics Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
CellGenix GmbH
Regen Biopharma Inc.
Lonza Group
Kiadis Pharma
Taiga Biotechnologies, Inc.
Takeda Pharmaceutical Company Limited
Escape Therapeutics, Inc.
Bluebird Bio
Talaris Therapeutics, Inc.
Marker Therapeutics Inc.
Stempeutics Research Pvt Ltd.
“*” marked represents similar segmentation in other categories in the respective section.